07.16.19

Genentech/Roche Complete Enrollment in Archway Phase 3 Study of the Port Delivery System with Ranibizumab in Wet AMD

Source: Genentech

06.17.19

Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMD

Source: Ribomic

04.25.19

Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseases

Source: Aerie Pharmaceuticals

04.18.19

Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMD

Source: Innovent Biologics

04.15.19

Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMD

Source: Novartis

03.25.19

Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMD

Source: Alkahest

03.07.19

Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimab

Source: Genentech

02.21.19

Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMD

Source: Ocular Therapeutix

01.03.19

Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseases

Source: Exonate

12.18.18

Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based OCT Closer to Market

Source: Notal Vision

View more stories